The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
 
Georgina V. Long
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Provectus; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MERCK; Novartis; Provectus; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; Immunocore; Incyte; MedIm; Merck; Merck Serono; Novartis; Pfizer; Rinat; Roche
 
F. Stephen Hodi
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Donald P. Lawrence
No Relationships to Disclose
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
Matteo S. Carlino
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis
 
Rosalie Anne Fisher
Honoraria - MSD
Consulting or Advisory Role - MSD
 
Wilson H Miller
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
 
Michele Maio
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
 
Marcus Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
 
Paola Queirolo
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
 
Pier Francesco Ferrucci
Consulting or Advisory Role - Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
 
Teresa M. Petrella
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Roche
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Yingjie Huang
Employment - GlaxoSmithKline; Novartis
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Scot Ebbinghaus
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; MedImmune; Merck; Novartis; Pierre Fabre